TTVR 早期可行性研究
经导管三尖瓣置换系统经股动脉系统的早期可行性研究
The objective of this early feasibility study is to gain early clinical insight into the performance of the Intrepid transcatheter tricuspid valve replacement (TTVR) system intended for transfemoral access to deliver a self-expanding bioprosthetic valve within the tricuspid valve.
研究概览
地位
地位
干预/治疗
干预/治疗
详细说明
Multi-center, prospective, non-randomized, investigational, and pre-market.
研究类型
研究类型
注册 (估计的)
注册
阶段
阶段
- 不适用
联系人和位置
学习地点
-
-
Alabama
-
Birmingham、Alabama、美国、35233
- University of Alabama at Birmingham (UAB) Hospital
-
-
Arizona
-
Phoenix、Arizona、美国、85016
- Abrazo Arizona Heart Hospital
-
-
California
-
Los Angeles、California、美国、90048
- Cedars Sinai Medical Center
-
San Francisco、California、美国、94115
- California Pacific Medical Center
-
-
Connecticut
-
Hartford、Connecticut、美国、06102
- Hartford Hospital
-
-
Georgia
-
Atlanta、Georgia、美国、30308
- Emory University Hospital Midtown
-
-
Michigan
-
Ann Arbor、Michigan、美国、48109
- University of Michigan Health System - University Hospital
-
Grand Rapids、Michigan、美国、49503
- Corewell Health
-
-
Minnesota
-
Minneapolis、Minnesota、美国、55407
- Abbott Northwestern Hospital
-
-
Montana
-
Missoula、Montana、美国、59802
- Providence Saint Patrick Hospital
-
-
New York
-
New York、New York、美国、10029
- The Mount Sinai Hospital
-
New York、New York、美国、10032
- New York-Presbyterian Hospital Columbia University Medical Center
-
The Bronx、New York、美国、10467
- Montefiore Medical Center
-
-
Ohio
-
Cincinnati、Ohio、美国、45242
- The Christ Hospital
-
Cleveland、Ohio、美国、44106
- University Hospitals Cleveland Medical Center
-
Columbus、Ohio、美国、43214
- OhioHealth Riverside Methodist Hospital
-
-
Oregon
-
Portland、Oregon、美国、97239
- Oregon Health & Science University Hospital
-
-
Pennsylvania
-
Harrisburg、Pennsylvania、美国、17101
- UPMC Pinnacle Harrisburg Campus
-
-
Texas
-
Houston、Texas、美国、77030
- Houston Methodist Hospital
-
-
Wisconsin
-
Milwaukee、Wisconsin、美国、53125
- Aurora Saint Lukes Medical Center
-
-
参与标准
资格标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Heart Team agrees that patient is deemed symptomatic despite medical therapy (including obligatory diuretic) and a candidate for bioprosthetic tricuspid valve replacement
- Subject is at an intermediate or greater estimated risk of mortality with tricuspid valve surgery as determined by the local Heart Team
- Subjects with severe symptomatic primary and / or secondary tricuspid regurgitation determined by the Echocardiography Core Lab assessment of a qualifying transthoracic echocardiogram (TTE) and transesophageal echocardiogram (TEE)
- New York Heart Association (NYHA) Function Class II or greater
- Subject anatomically suitable for the Intrepid TTVR delivery system including transfemoral access
- Subject and the treating physician agree that the subject will return for all required post-procedure follow-up visits
- Subject meets the legal minimum age to provide informed consent based on local regulatory requirements
Exclusion Criteria:
- Estimated life expectancy of less than 24 months due to associated non-cardiac co-morbid conditions
- Anatomic contraindications for Intrepid™ TTVR (e.g., annular dimensions)
- Evidence of intracardiac mass, inferior vena cava, or femoral venous mass or thrombus
- Implanted with venous stents (iliac and/or femoral) or inferior vena cava (IVC) filter or congenital abnormalities of the IVC that would preclude ability for transfemoral access of delivery system
- Echocardiographic evidence of severe right ventricular dysfunction
- Left ventricular ejection fraction (LVEF) <30 as measured by resting echocardiogram within 30 days of the Index Procedure
- Need for emergent or urgent surgery
- Untreated clinically significant coronary artery disease requiring revascularization
- Carcinoid tricuspid regurgitation
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
手臂数量
武器和干预
参与者组/臂参与者组/臂 |
干预/治疗干预/治疗 |
|---|---|
|
实验性的:Primary Cohort
Device: Intrepid TTVR System |
Device: Intrepid™ TTVR System |
研究衡量的是什么?
主要结果指标
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Rate of implant or delivery related serious adverse events
大体时间:Through 30 days post-procedure
|
Rate of implant or delivery related serious adverse events |
Through 30 days post-procedure
|
次要结果测量
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Successful access, delivery of implant, and retrieval of the delivery system assessed by definitions per Mitral Valve Academic Research Consortium (MVARC)
大体时间:During Procedure
|
For procedural success to be present, device success must have been achieved without major clinical complications as detailed per clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement (part 2: endpoint definitions) |
During Procedure
|
|
Change in TR Grade from baseline
大体时间:Through 30 days post-procedure
|
Change in TR Grade from baseline |
Through 30 days post-procedure
|
|
Rate of no significant TV stenosis
大体时间:Through 30 days post-procedure
|
Rate of no significant TV stenosis |
Through 30 days post-procedure
|
|
Change in NYHA Class from baseline
大体时间:Through 30 days post-procedure
|
Change in NYHA Class from baseline |
Through 30 days post-procedure
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
学习开始
初级完成 (实际的)
初级完成
研究完成 (估计的)
研究完成
研究注册日期
首次提交
首次提交
首先提交符合 QC 标准的
首先提交符合 QC 标准的
首次发布 (实际的)
首次发布
研究记录更新
最后更新发布 (实际的)
最后更新发布
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
最后验证
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.